Local biotech invests in erectile dysfunction drug

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

The company – which specializes in repurposing drugs already approved for other purposes – has signed a letter of intent to license a sublingual formation for drugs used to treat erectile dysfunction. Sublingual formations (which allow drugs to be dissolved under the tongue) absorb more quickly and therefore take effect sooner.

"We expect to move this product through pivotal trials and through regulatory approval over the next year and intend to begin marketing within two years," said Pacific Therapeutics CEO Douglas Unwin.

"We expect to complete the license in the first quarter of 2013, and move rapidly to the late-stage clinical trials and marketing."

In 2006, the market for drugs for treating erectile dysfunction exceeded $3 billion, the company said.

Pacific Therapeutics has two other drugs in the pipeline, both of which are for the treatment of scarring of human tissue.

Its lead product, PTL-202, is a combination of drugs being tested for efficacy in treating idiopathic pulmonary fibrosis, a progressive scarring of the lungs. The drug is already approved by the Food and Drug Administration in the U.S. and is currently in stage one of clinical trials.

nbennett@biv.com

@nbennett_biv

comments powered by Disqus

More from Technology

BC Tech touts Cascadia links ahead of federal government’s skilled foreign workers ...

Association venturing to Seattle to draw more technology talent north

Read Article

SFU Surrey researcher tests tool to help at-risk youth

Mental health treatment aimed at assisting Lower Mainland’s largest youth population

Read Article

BIV on Global BC May 18, 2017: Trudeau at Microsoft summit; Housing ...

Hayley Woodin discusses Trudeau promoting Canadian tech at Microsoft summit. Plus: What are the chances of Canada's housing market going bust?

Read Article

Vancouver biotech Novelogics partners with CDRD to advance cancer treatment

Read Article

Body heat: Young tech workers drive market migration

Vancouver technology companies find employees want to be close to where their peers are – and, increasingly, that is not in a shiny downtown office ...

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×